Peripheral blood stem cells in acute myeloid leukemia: Biology and clinical applications

Haematologica

Volumn 81, Issue 1, 1996, Pages 77-92

  Aglietta, Massimo ^b   De Vincentiis, Armando ^b   Lanata, Luigi ^b   Lanza, Francesco ^b   Lemoli, Roberto M ^b   Menichella, Giacomo ^b   Tafuri, Agostino ^b   Zanon, Paola ^b   Tura, Sante ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; ANTHRACYCLINE; CD34 ANTIGEN; COLONY STIMULATING FACTOR; COLONY STIMULATING FACTOR RECEPTOR; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; INTERLEUKIN 3; STEM CELL FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIGEN EXPRESSION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW PURGING; CANCER REGRESSION; CELL KINETICS; COLONY FORMING UNIT GM; HEMATOPOIETIC STEM CELL; HUMAN; NONHUMAN; REVIEW; STEM CELL TRANSPLANTATION;

ACUTE DISEASE; ANIMALS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, EXPERIMENTAL; LEUKEMIA, MYELOID; TRANSPLANTATION, AUTOLOGOUS;

EID: 0030324676     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (128)

1. Carlo Stella C, Cazzola M, De Fabritiis P, et al. CD34-positive cells: biology and clinical applications. Haematologica 1995; 80:367-87.
2. Siena S, Bregni M, Di Nicola M, et al. Durability of hematopoiesis following autografting with peripheral blood hematopoietic progenitors. Ann Oncol 1994; 5:935-41.
3. To LB. Is our current strategy in manipulating hemopoiesis in autologous transplantation correct? Stem Cells 1993; 11: 283-9.
4. Majolino I, Aversa F, Bacigalupo A, Bandini G, Arcese W, Reali G. Allogeneic transplants of the rhG-CSF-mobilized peripheral blood stem cells (PBSC) from normal donors. Haematologica 1995; 80:40-3.
5. Yin M, Silvestri FF, Banavali SD, et al. Clonogenic potential of myeloid leukemia cells in vitro is restricted to leukemia cells expressing the CD34 antigen. Eur J Cancer 1993; 29A: 2279-83.
6. Carlo-Stella C, Mangoni L, Almici C, Frassoni F, Fiers W, Rizzoli V. Growth of CD34: acute myeloblastic leukemia colony-forming cells in response to recombinant hemopoietic growth factors. Leukemia 1990; 4:561-6.
7. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367:645-8.
8. Ikeda H, Kanakura Y, Tamaki T, et al. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood 1991; 78:2962-8.
9. Broudy VC, Smith FO, Lin N, Zsebo K, Egrie J, Berstein ID. Blasts from patients with acute myelogenous leukemia express functional receptors for stem cell factor. Blood 1992; 80:60-7.
10. Motoji T, Watanabe M, Uzumaki H, et al. Granulocyte colony-stimulating factor (G-CSF) receptors on acute myeloblastic leukemia cells and their relationship with the proliferative response to G-CSF in clonogenic assay. Br J Haematol 1991; 77:54-9.
11. Budel LM, Touw IP, Delwel R, Clark SC, Lowenberg B. Interleukin-3 and granulocyte-monocyte colony stimulating factor receptors on acute myelocytic leukemia cells and relationship to the proliferative response. Blood 1989; 74:565-71.
12. Pietsch T, Kyas U, Steffens U, et al. Effects of human stem factor (c-kit ligand) on proliferation of myeloid leukemia cells: heterogeneity in response and synergy with other hematopoietic growth factors. Blood 1992; 80:1199-206.
13. Piacibello W, Sanavio F, Bresso P, et al. Stem cell factor improvement of proliferation and maintenance of hemopoietic progenitors in myelodysplastic syndrome. Leukemia 1994; 8:250-7.
14. Carlo Stella C, Rizzoli V. Stem cells and stem cell factor(s). Haematologica 1995; 80:1-4.
15. Miyajima A, Mui ALF, Ogorochi T, Sakamaki K. Receptors for granulocyte-macrophage colony stimulating factor, interleukin-3 and interleukin-5. Blood 1993; 82:1960-74.
16. Lowenberg B, Touw IP. Hemopoietic growth factors and their receptors in acute leukemia. Blood 1993; 81:281-92.
17. Mui ALF, Miyajima A. Interleukin-3 and granulocyte-macrophage colony-stimulating factor receptor signal transduction. Proc Soc Exp Biol Med 1994; 206:284-8.
18. Begley CG, Metcalf D, Nicola NA. Primary human myeloid leukemia cells: comparative responsiveness to proliferative stimulation by GM-CSF or G-CSF and membrane expression of CSF receptors. Leukemia 1987; 1:1-8.
19. Aglietta M, DeFelice L, Stacchini A, et al. Effect of hemopoietic growth factors on the proliferation of acute myeloid and lymphoid leukemias. Leuk Lymphoma 1990; 2:207-14.
20. Damiani D, Michieli M, Revignas MG, et al. Proliferation and maturation effects of in vivo granulocyte-macrophage colony stimulating factor in acute non-lymphocyte leukemia. Haematologica 1992; 77: 25-9.
21. Kondo S, Okamma S, Asano Y, Harada M, Niko Y. Human granulocyte colony stimulating factor receptors in acute myelogenous leukemia. Eur J Haematol 1991; 46:223-30.
22. Sachs L, Lotem J. Control of programmed cell death in normal and leukemic cells: new implications for therapy. Blood 1993; 82:15-21.
23. Aglietta M, De Felice L, Stacchini A, et al. In vivo effect of granulocyte-macrophage colony-stimulating factor on the kinetics of human acute myeloid leukemia cells. Leukemia 1991; 5:979-84.
24. Bettelheim P, Valent P, Andreeff M, et al. Recombinat human granulocyte-macrophage colony stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 1991; 77:700-11.
25. Estey E, Thall P, Andreeff M, et al. Use of granulocyte colony-stimulating factor before, during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994; 12:671-8.
26. Ohno R, Naoe T, Kanamaru A, et al. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood 1994; 83:2066-92.
27. Giralt S, Escudier S, Kantarjian H, et al. Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogenic bone marrow transplantation. N Engl J Med 1993; 329:757-61.
28. Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukmia. N Engl J Med 1995; 332:1671-7.
29. Dombret H, Chastang C, Fenaux P, et al. A controlled study of recombinant human granulocyte colony stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 1995; 332:1678-83.
30. Lajtha LG. On the concept of the cell cycle. J Cell Comp Physiol 1963; 62:143-5.
31. Hodgson GS, Bradley TR. Properties of haematopoietic stem cells surviving 5-fluorouracil treatment: evidence for a preCFU-S cell? Nature 1979; 281:381-2.
32. Leary AG, Hirai Y, Kishimoto T, Clark SG, Ogawa M. Survival of hemopoietic progenitors in GO does not require early hemopoietic regulators. Proc Natl Acad Sci USA 1989; 86:4535-9.
33. Till JE, McCulloch EA, Siminovitch L. A stochastic model of stem cell proliferation, based on the growth of spleen colony-forming cells. Proc Natl Acad Sci USA 1964; 51:29-34.
34. Minden MD, Till JE, McCulloch EA. Proliferative state of blast cell progenitors in acute myeloblastic leukemia (AML). Blood 1978; 52:592-6.
35. 3H-thymidine for 8-10 days. Cancer 1970; 25:1237-60.
36. Gavosto F, Pileri A, Gabutti V, Masera P. Non self-maintaining kinetics of proliferating blasts in human acute leukaemia. Nature 1967; 216:188-9.
37. Andreeff M, Darzynkiewicz Z, Sharpless TK, Clarkson BD, Melamed MR. Discrimination of human leukemia subtypes by flow cytometric analysis of cellular DNA and RNA. Blood 1980; 55:282-93.
38. Raza A, Maheshwari Y, Preisler HD. Differences in cell cycle characteristics among patients with acute nonlymphocytic leukemia. Blood 1987; 69:1647-53.
39. Lista P, Brizzi MF, Rossi M, Resegotti L, Clark SC, Pegoraro L. Different sensitivity of normal and leukaemic progenitor cells to Ara-C and IL-3 combined treatment. Br J Haematol 1990; 76:21-6.
40. Tafuri A, Andreeff M. Kinetic rationale for cytokine-induced recruitment of myloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 1990;12:826-34.
41. +). Leukemia 1995; 9:450-7.
42. + cells in the absence of other growth factors. Exp Hematol 1995; 23:413-21.
43. Hunter T, Pines J. Cyclins and Cancer II: cyclin D and CDK inhibitors come of age. Cell 1994; 79:573-82.
44. + (MY10). Leukemia 1988; 2:661-6.
45. Campos L, Guyotat D, Archimbaud E, et al. Surface marker expression in adult acute myeloid leukemia: correlations with initial characteristics, morphology and response to therapy. Br J Haematol 1989; 72:161-6.
46. + (MY10) positive acute nonlymphocytic leukemia. Am J Clin Pathol 1989; 91:265-70.
47. + (MY10). Br J Haematol 1990; 76:340-7.
48. Guinot M, Sanz G F, Sempere A, et al. Prognostic value of CD34 expression in de novo acute myeloblastic leukemia. Br J Haematol 1991; 78:533-4.
49. + and TdT determinations in patients with untreated de novo acute myeloid leukemia. Leukemia 1992; 6:1203-9.
50. + phenotype with shorter survival. Leukemia 1992; 6:93-9.
51. + antigen in acute myeloid leukemia. Leuk Lymphoma 1992; 7:425-9.
52. + positive acute myeloid leukemia: correlations with clinicopathologic features. Cancer Genet Cytogenet 1993; 71:119-24.
53. Lanza F, Rigolin M, Moretti S, Latorraca A, Castoldi G. Prognostic value of immunophenotypic characteristics of blast cells in acute myeloid leukemia. Leuk Lymphoma 1994; 13:81-5.
54. Smith FO, Lampkin B, Versteeg C, et al. Expression of lymphoid-associated cell surface antigens by childhood acute myeloid leukemia cells lacks prognostic significance. Blood 1992; 79:2415-22.
55. Kuerbit SJ, Civin CI, Krisher JP, et al. Expression of myeloid-associated and lymphoid-associated cell surface antigens in acute myeloid leukemia of childhood: a pediatric oncology group study. J Clin Oncol 1992; 10:1419-29.
56. + in acute myeloid leukemia. Br J Haematol 1992; 82:479-82.
57. Sperling C, Buchner T, Sauerland C, Fonatsch C, Thiel E, Ludwig W. CD34 expression in de novo acute myeloid leukemia. Br J Haematol 1993; 85:635-7.
58. + expression fails to predict the outcome in adult acute myeloid leukemia. Haematologica 1993; 78:151-5.
59. Del Poeta G, Stasi R, Venditti A, et al. Prognostic value of cell marker analysis in de novo acute myeloid leukemia. Leukemia 1994; 8:388-94.
60. + expression in childhood and adult de novo AML. Leuk Lymphoma 1995; 17:417-26.
61. Terstappen L, Safford M, Konemann S, et al. Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis. Leukemia 1991; 9:757-67.
62. van't Veer M, Kluin-Nelemans J, van Der Schoot C, van Putten W, Adriaansen H, van Wering E. Quality assessment of immunological marker analysis and the immunological diagnosis in leukemia and lymphoma: a multi-centre study. Br J Haematol 1992; 80:458-65.
63. Brando B, Sommaruga E. Nationwide quality control trial on lymphocyte immunophenotyping and flow cytometer performance in Italy. Cytometry 1993; 14:294-306.
64. Castoldi G, Liso V, Fenu S, Vegna L, Mandelli F. Reproducibility of the morphological diagnostic criteria for acute myeloid leukemia: the GIMEMA group experience. Ann Haematol 1993; 66:171-4.
65. Drexler H, Eckhard T, Wolf-Dieter L. Acute myeloid leukemias expressing lymphoid-associated antigens: diagnostic incidence and prognostic significance. Leukemia 1993; 7:489-98.
66. Kawada H, Ichikawa Y, Watanabe S, Nagao T, Arimori S. Flow cytometric analysis of cell surface antigen expressions on acute myeloid leukemia cell populations according to their cell size. Leukemia Res 1994;18:29-35.
67. Syrjala M, Ruutu T, Jansson SE. A flow cytometric assay of CD34-positive cell populations in the bone marrow. Br J Haematol 1994; 88:679-84.
68. Campana D, Pui CH. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 1995; 85:1416-34.
69. Greaves MF, Brown J, Molgaard HV, et al. Molecular features of CD34: a hemopoietic progenitor cell-associated molecule. Leukemia 1992; 6:31-6.
70. Sutherland DR, Marsh JCW, Davidson J, Baker MA, Keating A, Mellors A. Differential sensitivity of CD34 epitopes to cleavage by Pasteurella haemolytica glycoprotease: implications for purification of CD34-positive progenitor cells. Exp Hematol 1992; 20:590-9.
71. + cells: methodology and monoclonal antibodies. In: Wunder S, Serke S, Solovat H, Henon P, eds. Hematopoietic stem cell: the Mulhouse manual. Dayton: AlphaMed Press, 1994:141-8.
72. Greaves MF, Colman SM, Böhring HJ, et al. Report on the CD34 cluster workshop. In: Schlossman SF, Boumsell L, Gilks W et al, eds. Leucocyte typing V: White cell differentiation antigens. Oxford: Oxford University Press, 1995:840-7.
73. Silvestri F, Banavali S, Baccarani M, Preisler HD. Progenitor cell associated antigen CD34: biology and clinical applications. Haematologica 1992; 77:265-72.
74. + cells by percoll density gradients. A CML-based study design. In: Wunder E, Serke S, Sovalat H, Henon P, eds. Hematopoietic stem cells: the Mulhouse manual. Dayton: Alpha Med Press, 1994:255-70.
75. Slovak ML, Traweek ST, Willman CL, et al. Trisomy 11: an association with stem/progenitor cell immunophenotype. Br J Haematol 1995;90:266-73.
76. Lai J, Preudhomme C, Zandecki M, et al. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of p53 mutations. Leukemia 1995; 9:370-81.
77. + haematopoietic progenitor cells. Br J Haematol 1993; 84:24-30.
78. Craig W, Kay R, Cutler R, Lansdorp P. Expression of THY-1 on human haematopoietic progenitor cells. J Exp Med 1993; 177:1331-42.
79. + positive hemopoietic cells: biology and clinical applications. Blood Rev 1994; 8:113-24.
80. + leukemic cells assessed by different CD34 monoclonal antibodies. Leuk Lymphoma 1995 (in press).
81. Meckenstock G, Heyll A, Schneider E, et al. Acute leukemia coexpressing myeloid, B- and T-lineage associated markers: multiparameter analysis of criteria defining lineage commitment and maturational stage in a case of undifferentiated leukemia. Leukemia 1995; 9:260-4.
82. Mayer RI, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994; 331:896-903.
83. Cassileth PA, Linch E, Hines JD, et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1992; 79:1924-30.
84. Cassileth PA, Nowell PC, Larson RA. Acute leukemia. In: McArthur JR, Schrier S, eds. Hematology - 1993. St. Louis: The American Society of Hematology, 1993:38-48.
85. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic bone marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990; 76:1867-71.
86. Young JW, Papadopoulos EB, Cunningham I, et al. T-cell-depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission. Blood 1992; 79:3380-7.
87. Berlin MM, Horowitz MM, Rowlings PA, et al. 1993 Progress report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1993; 12:97-104.
88. Aversa F, Tabilio A, Terenzi A, et al. Successful engraftment of T-cell-depleted haploidentical three-loci incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cell to bone marrow inoculum. Blood 1994; 84:3948-55.
89. Cassileth PA, Andersen J, Lazarus HM, et al. Autologous bone marrow transplant in acute myeloid leukemia in first remission. J Clin Oncol 1993; 11:314-9.
90. Gorin NC, Labopin M, Meloni G, et al. Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: further evidence of the role of marrow purging by mafosfamide. Leukemia 1991; 5:896-904.
91. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995; 332:217-23.
92. To LB, Russel J, Moore S, et al. Residual leukemia cannot be detected in very early remission peripheral blood stem cell collection in acute non-lymphoblastic leukemia. Leuk Res 1987; 11:327-9.
93. Juttner CA, To LB, Haylock DN, et al. Circulating autologous stem cells collected in very early remission from acute non-lymphoblastic leukemia produce prompt but incomplete hemopoietic reconstitution after high dose melphalan or supralethal chemoradiotherapy. Br J Haematol 1985; 61:739-45.
94. Nagafuji K, Harada M, Takamatsu Y, et al. Evaluation of leukemic contamination in peripheral blood stem cell harvests by reverse transcriptase polymerase chain reaction. Br J Haematol 1993; 85:578-83.
95. Brenner MK, Rill DR, Moen RC, et al. Gene-marking to trace the origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341:85-6.
96. Gorin NC, Dicke K, Lowenberg B. High dose therapy for acute myelocytic leukemia treatment strategy: what is the choice? Ann Oncol 1993; 4 (Suppl. 1):59-80.
97. Bassan R, Barbui T. Remission induction therapy for adults with acute myelogenous leukemia: towards the ICE age? Haematologica 1995; 80:82-90.
98. Reiffers J, Korbling M, Labopin M, et al. Autologous blood stem cell transplantation versus autologous bone marrow transplantation for acute myeloid leukemia in first complete remission. Int J Cell Cloning 1992; 7(Suppl. 1):111.
99. Korbling M, Fliedner TM, Holle R, et al. Autologous blood stem cell (ABSCT) versus purged bone marrow transplantation (pABMT) in standard risk AML: influence of source and cell composition of the autograft on hemopoietic reconstitution and disease free survival. Bone Marrow Transplant 1991; 7:343-9.
100. Sanz MA, de la Rubia J, Sanz GF, et al. Busulfan plus cyclophosphamide followed by autologous blood stem cell transplantation for patients with acute myeloblastic leukemia in first complete remission: a report from a single institution. J Clin Oncol 1993; 11:1661-7.
101. To LB, Roberts MM, Haylock DN, et al. Comparison of hematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992; 9:277-84.
102. Siena S, Bregni M, Brando B, et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991; 77:400-9.
103. To LB, Haylock DN, Dyson PG, Thorp D, Roberts MM, Juttner CA. An unusual pattern of hemopoietic reconstitution in patients with acute myeloid leukemia transplanted with autologous recovery phase peripheral blood. Bone Marrow Transplant 1990; 6:109-14.
104. Bender JG, To LB, Williams S, Schwartzberg LS. Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1992; 1:329-42.
105. Kotasek D, Sheperd KM, Gage RE, et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992; 9:4-17.
106. Laporte FP, Gorin NC, Feuchtenbaum J, et al. Relapse after autografting with peripheral blood stem cells (Letter). Lancet 1987; 2:1393.
107. Yan Liu K, Akashi K, Harada M, Takamatsu Y, Niho Y. Kinetics of circulating haematopoietic progenitors during chemotherapy-induced mobilization with or without granulocyte colony-stimulating factor. Br J Haematol 1993; 84:31-8.
108. Onho R, Tomonaga M, Kobayashi T, et al. Effect of granulocyte colony-stimulating factor after intensive induction in relapsed or refractory acute leukemia. N Engl J Med 1990; 323:871-7.
109. Onho R, Hiraoka A, Tanimoto M, et al. No increase of leukemia relapse in newly diagnosed patients with acute myeloid leukemia who received granulocyte colony-stimulating factor for life-threatening infection during remission induction and consolidation therapy. Blood 1993; 81:561-2.
110. Hagenbeek A, Schultz FW, Martens ACM. In vitro or in vivo treatment of leukemia to prevent relapse after autologous bone marrow transplantation. In: Dicke KA, Spitzer G, Jagannath S, eds. Autologous bone marrow transplantation: Proceedings of the Fourth International Symposium. MD Anderson Hospital Publ., 1989:107-12.
111. Gribben JH, Freedman AS, Neuberg D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991; 325:1525-33.
112. Brenner MK, Rill DR, Moen RC, et al. Gene-marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 1993; 341:85-6.
113. Gulati SC, Lemoli RM, Acaba L, Igarashi T, Wasserheit C, Fraig M. Purging in autologous and allogeneic bone marrow transplantation. Curr Opin Oncol 1992; 4:543-50.
114. Sharkis SJ, Santos GW, Colvin MO. Elimination of acute myelogenous leukemia cells from marrow and tumor suspensions in the rat with 4-hydroperoxycyclophosphamide. Blood 1980; 55:521-3.
115. Siena S, Castro-Malaspina H, Gulati SC, et al. Effects of in vitro purging with 4-hydroperoxycyclophosphamide on the hematopoietic and microenvironment elements of human bone marrow. Blood 1985; 65:655-62.
116. Bullock G, Tang C, Tourkina E, et al. Effect of combined treatment with interleukin-3 and interleukin-6 on 4-hydroperoxycyclophosphamide induced programmed cell death or apoptosis in human myeloid leukemia cells. Exp Hematol 1993; 21:1640-4.
117. Skorski T, Kawalec M, Hoser G, Ratajczac M, Gnatowski B, Kawiak J. The kinetic of immunologic and hematologic recovery in mice after lethal total body irradiation and reconstitution with syngeneic bone marrow cells treated or untreated with mafosfamide (Asta Z 7654). Bone Marrow Transplant 1988; 3:543-51.
118. Lemoli RM, Gulati SC. In vitro cytotoxicity of VP-16-213 and nitrogen mustard: Agonistic on tumor cells but not on normal human bone marrow progenitors. Exp Hematol 1990; 18:1008-12.
119. Lemoli RM, Gasparetto C, Scheinberg DA, et al. Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination. Blood 1991; 77: 1829-36.
120. Lemoli RM, Igarashi T, Knizewski M, et al. Dye-mediated photolysis is capable of eliminating drug-resistant tumor cells. Blood 1993; 31:793-800.
121. Chang J, Morgenstern GR, Coutinho LH, et al. The use of bone marrow cells grown in long-term culture for autologous bone marrow transplantation in acute myeloid leukemia: an update. Bone Marrow Transplant 1989; 4:5-10.
122. Rowley SD, Jones RJ, Piantadosi S, et al. Efficacy of ex vivo purging for autologous bone marrow transplantation in the treatment of acute non lymphoblastic leukemia. Blood 1989; 74:501-6.
123. Miller CB, Zenhbauer BA, Piantadosi S, Rowley SD, Jones RJ. Correlation of occult clonogenic leukemia drug sensitivity with relapse after autologous bone marrow transplantation. Blood 1991; 78:1125-31.
124. Gorin NC, Aegerter P, Auvert P, et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission. A European survey of the role of marrow purging. Blood 1990; 75:1606-14.
125. Labopin M, Gorin NC. Autologous bone marrow transplantation in 2502 patients with acute leukemia in Europe: a retrospective study. Leukemia 1992; 6 (Suppl. 4):95-9.
126. Gulati SC, Acaba L, Yahalom J, et al. Autologous bone marrow transplantation for acute myelogenous leukemia using 4-hydroperoxycyclophosphamide and VP-16 purged bone marrow. Bone Marrow Transplant 1992; 10:129-34.
127. Laporte JP, Douay L, Lopez M, et al. One hundred twenty-five adult patients with primary acute leukemia autografted with marrow purged with mafosfamide: a 10-year single institution experience. Blood 1994; 84:3810-8.
128. Roberts AW, Metcalf D. Noncycling state of peripheral blood progenitor cells mobilized by granulocyte colony-stimulating factor and other cytokines. Blood 1995; 86:1600-5.